For instance, Sarah Lofgren, an infectious disease doctor at the University of Minnesota Medical School in Minneapolis - they're testing hydroxychloroquine there to prevent COVID-19. March. The first hydroxychloroquine study appeared as a preprint on March 17, and Trump approved the drug on March 19.
The outcomes demonstrated that the drugs augmented the risk of dying by over 35% and also doubled the risk of heart problems.
He said the concern related only to the use of hydroxychloroquine and chloroquine for Covid-19, adding that the drugs are accepted treatments for people with malaria and auto-immune diseases. Trump has been a particularly strong supporter of hydroxychloroquine, calling it a "game changer" early on.
Despite the World Health Organization dropping hydroxychloroquine from its study into experimental coronavirus treatments, a White House official said that the USA president is feeling "absolutely great" after taking a two-week dose of the drug.
One article on the drug titled "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", published May 22, found that the drug had no benefit.More news: Attack on Taiwan still an option: China general
Anurag Agrawal, physician and Director, Institute of Genomics and Integrative Biology - a CSIR institute - as well as Rajeeva Karandikar, Director, Chennai Mathematical Institute, says the World Health Organization's decision to suspend trials of the drug was a "knee-jerk" reaction.
Published last week in The Lancet, the large-scale study suggested the malaria drugs could be risky to people with severe cases of Covid-19, increasing the risk of abnormal heart rhythms and even death.
It has also become the most high profile, partly because of comments by US President Donald Trump - who announced this month he was taking the drug as a preventive measure against coronavirus. "We decided we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm" of the trial.
"Whether [in doctors offices] in the cities or in the hospital, this. should not be prescribed for patients with COVID-19", the French health ministry declared in a statement published Wednesday morning.
However, more recent studies have raised serious safety issues.More news: Federal officer killed guarding courthouse near protest
More unsafe is the fact that the drug is widely available, and some people may want to use it because the president said it is good or because they have allegedly treated it with it.
While the World Health Organization has claimed the drug poses severe risks to patients, not all medical professionals believe banning the drug is appropriate.
Swiss drugmaker Novartis is pushing ahead with its US study involving 440 patients, while French company Sanofi declined to comment on the future of its two trials.
Last week, the study in the Lancet analysed data from almost 15,000 patients with Covid-19 who received the drug alone or in combination with antibiotics, against a control group of 81,000 who did not receive it.
Researchers continue to evaluate the possible use of hydroxychloroquine, which is used to treat malaria and lupus, to fight the coronavirus, with at least two studies under way in the U.S. As NPR's Joe Palca reports, the drug has been found to be able to prevent replication of the coronavirus.More news: US Astronauts Blast Into Space Aboard SpaceX Rocket
Experts are still divided over what medication should be used to treat COVID-19.